+91-8668442535
Home / Biotechnology / Liquid Bio

Liquid Biopsy Market By Analytes (Circulating Tumor Cells (CTCs), Circulating Tumor Dna (CtDNA), Extracellular Vesicles (EVs)), By Application (Prognosis, Diagnosis, Therapy Monitoring) - Market Growth, Future Prospects and Competitive Analysis, 2016 - 2022

Biomarker-based diagnostics have already offered great advances in cancer diagnosis, prognosis, staging, and therapy selection in the past decade. However, the tissue-based detection approach produces a major drawback in terms of invasion for sample collection. Over the last few years, several cancer biomarker research studies have moved their focus to the analysis of biomarkers found in biological fluids, which offer minimal invasion and longer disease tracking - liquid biopsy. As a result, several cancer diagnostic companies and startups have accepted the challenge of commercializing liquid biopsy tools in the market.

For this study, the liquid biopsy market is studied by analytes and applications. Based on analytes, this report studies circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicle (SV) segments. Liquid biopsy techniques find application in cancer prognosis, diagnosis, and therapy monitoring. This report provides market size and forecast (USD Mn) for such considered segments for 2014-2022, along with their respective CAGRs (value %) for 2016-2022, considering 2015 as the base year.

Geographically, the global liquid biopsy market is categorized into the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
  • Middle East and Africa
  • Latin America

The market size and forecast for the period 2014-2022, along with the CAGRs for the period 2016-2022 for the mentioned segments, are also presented in this study.

This study also provides qualitative assessment tools for the readers that offer the overall status and trends in the liquid biopsy market. Such sections include market dynamics (drivers, challenges, prospects), major commercial events, and major research events. In addition, for competitive assessment, tools such as attractive investment proposition and fractal map analysis (by key market players) are also presented in this study. Finally, this report concludes with a company profiles section that highlights major information about key companies operating in the liquid biopsy market. Some of the major market players covered in this section include Myriad Genetics, Qiagen, Trovagene, Natera, Foundation Medicine, and others. The key information provided on these players is based on parameters such as business description, financial health, product portfolio, and news coverage.

Based on the analyte types, the global liquid biopsy market is classified as follows:

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA) Fragments
  • Extracellular Vesicles (EVs)

Among the mentioned analyte types, CTCs demonstrate the longest history of being subject to liquid biopsy. CTC-based technologies have been in practice for over a decade, and their IVD use has FDA approval. ctDNA is a more recent entrant in the liquid biopsy market and is rapidly becoming an alternative to CTC assays. EVs, furthermore, are the latest addition to the liquid biopsy portfolio and are the least developed so far. Approximately a third of the overall liquid biopsy research is concentrated on EV development. EVs represent a set of the source of circulating biomarkers in lipid coat encapsulation. The biomarker cargo associated with EVs includes exosomes, microvesicles, apoptotic bodies, large oncosomes, and others.

The application areas studied for analyzing the liquid biopsy market are:

  • Prognosis
  • Diagnosis
  • Therapy monitoring
  • Others

Liquid biopsy can assist clinicians in determining cancer prognosis, stratification of patients to determine the best possible treatment modality, and assess tumor resistance mechanisms. Molecular characterization of tumors is facilitated through liquid biopsy, and its non-invasive nature paves the way for repeated sampling to scrutinize genetic changes during any period by avoiding tissue biopsy. Disease prognosis currently takes the highest share in the liquid biopsy applications market, whereas diagnostics and therapy monitoring closely competes with each other. Liquid biopsy can efficiently monitor the effectiveness of the treatment regimen, thus facilitating treatment optimization and possible alterations. As the nature of tumors changes over time, liquid biopsy offers the benefit of analyzing such dynamics and providing information for possible treatment change. In cases where particular genotypes are identified in patients, liquid biopsy allows early detection of cancer before the occurrence of overt symptoms.

Based on geographical segmentation, the global liquid biopsy market is studied for:

  • North America
  • US.
  • Canada
  • Europe
  • UK.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
  • Latin America
  • Middle East and Africa

North America is the current geographical leader in the liquid biopsy market. High demand for the latest diagnostic modules, coupled with greater awareness between both patients and caregivers, plays a vital growth in the dominance of this region. Additionally, several giant market players and new startups operating in this market are domiciled in North America and Europe, thus allowing early bird advantage to these regions. A large number of research activities being conducted in the region also is a prime phenomenon in North American and Europe markets. However, challenged reimbursements may hold back the growth of this market to a certain extent. The introduction of cost-effective solutions and rapid approvals in Latin America and Asia-Pacific will serve as the prime growth drivers in these regions.

Frequently asked questions :

The market for Liquid Biopsy Market is expected to reach US$ 10,850.3 Mn By 2022

The Liquid Biopsy Market is expected to see significant CAGR growth over the coming years, at 24.7%.

The report is forecasted from 2016-2022.

The base year of this report is 2021.

Myriad Genetics, Oncocyte, RainDance Technologies, Veracyte, Foundation Medicine,are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  May 2016
Category:  Biotechnology
Report ID:   57830
Report Format:   PDF
Pages:   120
Rating:    4.4 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support